8-K: Bio-Path Holdings Completes Second Dose Cohort in BP1002 Leukemia Trial

Bio-Path Holdings has successfully completed the second, higher dose cohort in its Phase 1/1b clinical trial of BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients.

Summary

• Bio-Path Holdings has completed the second dose cohort of its Phase 1/1b clinical trial for BP1002, a drug targeting the Bcl-2 protein in AML patients.
• The trial is evaluating BP1002's effectiveness in treating refractory/relapsed AML, including patients resistant to venetoclax.
• The second dose cohort used a 40 mg/m2 dose, following an initial 20 mg/m2 dose, with a total of six patients evaluated across the two dose levels.
• The trial will now pause for an FDA data review before continuing with a higher dose of 60 mg/m2.
• The Phase 1b portion of the study will assess BP1002 in combination with decitabine after the monotherapy cohorts are completed.
• BP1002 targets Bcl-2 at the mRNA level, potentially overcoming resistance mechanisms seen with venetoclax, which targets the protein directly.
• Preclinical studies have shown BP1002 to be a potent inhibitor against the Bcl-2 target with a benign safety profile.

Sentiment

Score: 7

Explanation: The document is positive due to the successful completion of a trial milestone and the potential of the drug, but there are risks associated with clinical trials and funding.

Positives

• The successful completion of the second dose cohort is an important milestone for the study.
• Enrollment rates for the trial have been good.
• BP1002 has shown a benign safety profile in preclinical studies.
• BP1002 has the potential to address venetoclax resistance in AML patients.
• The trial is progressing to higher doses and combination therapy.

Risks

• The company's ability to raise additional capital is a risk to its operations.
• Clinical development of the technology may not be successful.
• The timing of enrollment and release of data in clinical studies is uncertain.
• Results from later stage clinical trials may not be consistent with earlier stage trials.
• The company faces risks related to intellectual property rights and patents.
• Global pandemics, such as COVID-19, pose risks and uncertainties.

Future Outlook

The company expects to continue dose testing at the next planned higher dose of 60 mg/m2 after a brief data review by the FDA, and then commence the Phase 1b portion of the study assessing BP1002 in combination with decitabine.

Management Comments

• Peter Nielsen, President and CEO, stated they are delighted to safely progress through the second, higher dose cohort.
• Peter Nielsen mentioned they look forward to advancing the study in even higher doses with the hope that they can sooner reach the combination therapy segment of the Phase 1/1b study.

Industry Context

The announcement is relevant to the oncology space, particularly in the treatment of AML, where there is a need for therapies that can overcome resistance to existing treatments like venetoclax. The use of RNAi technology to target Bcl-2 at the mRNA level is a novel approach.

Comparison to Industry Standards

• The standard of care for AML patients not eligible for intensive chemotherapy is venetoclax in combination with a hypomethylating agent or low-dose cytarabine.
• Many patients develop resistance to venetoclax, highlighting the need for alternative treatments like BP1002.
• A published study found that AML patients who had relapsed from frontline venetoclax-based treatment had a median survival of less than 3 months, indicating a significant unmet need.
• Companies like AbbVie and Genentech market venetoclax, which is a direct competitor to the approach Bio-Path is taking.

Stakeholder Impact

• Shareholders may view the trial progress positively.
• Patients with refractory/relapsed AML may benefit from the development of BP1002.
• The company's employees are involved in the clinical trial process.

Next Steps

• The clinical trial will pause for a brief data review by the FDA.
• Dose testing will continue at the next planned higher dose of 60 mg/m2.
• The Phase 1b portion of the study will commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine.

Key Dates

Keywords

BP1002, AML, Leukemia, Bcl-2, RNAi, Clinical Trial, Venetoclax, Refractory, Relapsed, Oncology, Cancer, Bio-Path Holdings